A new trading day began on Tuesday, with Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) stock price down -0.89% from the previous day of trading, before settling in for the closing price of $0.30. ADAP’s price has ranged from $0.20 to $1.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 193.37%. Meanwhile, its annual earnings per share averaged -77.66%. With a float of $226.52 million, this company’s outstanding shares have now reached $255.94 million.
Let’s determine the extent of company efficiency that accounts for 506 employees. In terms of profitability, gross margin is 95.32%, operating margin of -38.62%, and the pretax margin is -39.06%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 37.29%. The most recent insider transaction that took place on Jan 17 ’25, was worth 3,243. In this transaction Chief Medical Officer of this company sold 5,584 shares at a rate of $0.58, taking the stock ownership to the 7,510 shares. Before that another transaction happened on Jan 17 ’25, when Company’s Chief Patient Supply Officer sold 5,584 for $0.58, making the entire transaction worth $3,243. This insider now owns 7,510 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -77.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.84% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Here are Adaptimmune Therapeutics Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.29, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.05 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Looking closely at Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP), its last 5-days average volume was 0.77 million, which is a drop from its year-to-date volume of 1.54 million. As of the previous 9 days, the stock’s Stochastic %D was 77.21%. Additionally, its Average True Range was 0.03.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 21.41%, which indicates a significant decrease from 79.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.98% in the past 14 days, which was lower than the 115.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3364, while its 200-day Moving Average is $0.7075. However, in the short run, Adaptimmune Therapeutics Plc ADR’s stock first resistance to watch stands at $0.3122. Second resistance stands at $0.3244. The third major resistance level sits at $0.3305. If the price goes on to break the first support level at $0.2939, it is likely to go to the next support level at $0.2878. Should the price break the second support level, the third support level stands at $0.2756.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
With a market capitalization of 76.78 million, the company has a total of 257,232K Shares Outstanding. Currently, annual sales are 178,030 K while annual income is -70,810 K. The company’s previous quarter sales were 3,220 K while its latest quarter income was -74,220 K.
